One case series of patients with refractory MAS+/− lung disease treated with moderate dosing of the chemotherapy agent etoposide (a mainstay of treatment in primary haemophagocytic lymphohistiocytosis (HLH) [36]) included five patients with Still’s [37]. The gene discussed is MAS1; the disease is lung disorder.